Breaking News Instant updates and real-time market news.

HAIN

Hain Celestial

$35.76

0.22 (0.62%)

, NKE

Nike

09:28
06/30/17
06/30
09:28
06/30/17
09:28

On The Fly: Pre-market Movers

HIGHER: Hain Celestial (HAIN), up 9.4% after Engaged Capital disclosed in a filing that it took a 9./9% stake, held talks with the company, and submitted seven board nominees... Nike (NKE), up 5.8% after reporting quarterly results... Bank of America (BAC), up 1.2% after Warren Buffett's Berkshire Hathaway (BRK.A, BRK.B) will exercise warrants to buy 700M Bank of America shares... E-Trade (ETFC), up 1% after the Wall Street Journal reported that the company will consider options, including a sale, if targets are not met. LOWER: Rite Aid (RAD), doqn 4.5% after being reinstated with an Underperform at Evercore ISI... Cara Therapeutics (CARA), down 25.3% after it announced results from its Phase 2b trial of oral CR845.

HAIN

Hain Celestial

$35.76

0.22 (0.62%)

NKE

Nike

BAC

Bank of America

ETFC

E-Trade

$37.68

-0.01 (-0.03%)

RAD

Rite Aid

CARA

Cara Therapeutics

$25.51

-1.44 (-5.34%)

  • 06

    Jul

HAIN Hain Celestial
$35.76

0.22 (0.62%)

06/30/17
JPMS
06/30/17
NO CHANGE
JPMS
Neutral
JPMorgan has doubts about Engaged's ability to create value at Hain
After Engaged Capital disclosed a 9.9% activist stake in Hain Celestial, JPMorgan analyst Ken Goldman says he has some doubts about how much can be done to "incrementally create value from here." The analyst thinks Hain can be improved fundamentally and sees some logic in trying to transform the board, but points out the company has already announced a 20% U.S. SKU reduction and the biggest cost savings program in U.S. food today. Further, Hain is unlikely to be sold outright and does not offer a compelling valuation, Goldman tells investors in a research note. He does not recommend shorting the stock, but tells investors to "be careful" before adding to positions. The analyst keeps a Neutral rating on Hain. The stock last night traded up 6% to $37.78.
06/23/17
BMOC
06/23/17
NO CHANGE
BMOC
Hain Celestial changes not adequately reflected in stock, says BMO Capital
BMO Capital analyst AmitSharma says that structural changes made by Hain should boost its growth and margins. The analyst says that these changes have not been adequately reflected in the stock. Shama adds that the the release of audited financial results for fiscal 2016 and the first three quarters of this year remove a "major overhang" on the shares. He thinks that the company is "well-positioned" to report strong EPS growth in fiscal 2018, and he keeps an Outperform rating on the stock.
06/23/17
06/23/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Caterpillar (CAT) downgraded to Hold from Buy at Deutsche Bank with analyst Nicole DeBlase saying risks are skewed to the downside as consensus estimates have risen and the recovery in mining A/M and incremental cross-cycle margin improvement are reflected in expectations. 2. Hain Celestial (HAIN) downgraded to Neutral from Overweight at JPMorgan with analyst Ken Goldman saying fundamentals have worsened more than feared and guidance seems "slightly" optimistic. 3. Baker Hughes (BHI) downgraded to Hold from Buy at Tudor Pickering. 4. Tanger Factory (SKT) downgraded to Underperform from Neutral at BofA/Merrill with analyst Craig Schmidt citing increased concerns about the moderate outlet space. 5. EnerNOC (ENOC) was downgraded to Market Perform from Outperform at Raymond James and to Neutral from Outperform at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/17
JEFF
06/29/17
NO CHANGE
Target $50
JEFF
Buy
Hain Celestial risk/reward 'very attractive,' says Jefferies
After spending three days on the road with management, Jefferies analyst Akshay Jagdale says the risk/reward at current share levels is "very attractive" for Hain Celestial. He continues to believe the company's total addressable market and earnings can double over the next three-to-five years. The analyst now has greater confidence in Hain's ability to achieve its targets and sees a pathway to positive scanner trends by early 2018. Jagdale keeps a Buy rating on the shares with a $50 price target.
NKE Nike

06/30/17
JEFF
06/30/17
NO CHANGE
Target $75
JEFF
Buy
Nike shares will return to 'marching higher,' says Jefferies
Jefferies analyst Randal Konik believes that with the FY18 guidance out of the way and solid core business fundamentals, shares of Nike "will return back to marching higher." The analyst reiterates a Buy rating on the shares with a $75 price target.
06/30/17
BARD
06/30/17
NO CHANGE
Target $65
BARD
Outperform
Nike results and outlook better than feared, says Baird
Baird analyst Jonathan Komp said Nike's Q4 results and guidance were better than feared and noted its key businesses are stabilizing. The analyst was encouraged by management's aggressive pivoting behind innovation, speed, and more direct consumer connections. Komp said investors with a 6-12 month time horizon should be accumulating shares at current levels. Komp reiterated his Outperform rating and raised his price target to $65 from $62 on Nike shares.
06/30/17
ADAM
06/30/17
NO CHANGE
Target $51
ADAM
Hold
Nike Q4 results low quality, guidance underwhelms, says Canaccord
Canaccord analyst Camilo Lyon said Nike's Q4 results were of poor quality despite reporting numbers better than he expected. Lyon maintained his Hold rating and $51 price target on Nike shares, citing continued deterioration of global futures orders, tough North American landscape, and its lowered guidance.
06/30/17
STFL
06/30/17
NO CHANGE
STFL
Nike reported 'solid' Q4 results, says Stifel
Stifel analyst Jim Duffy believes that Nike reported "solid" Q4 results, and the analyst thinks that the company's switch to a more direct consuemr engagement model will boost its results over the longer term. He keeps a Buy rating on the stock.
BAC Bank of America

04/24/17
04/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Loop Capital with analyst David Miller citing valuation following the stock hitting a 52-week high on Friday. The strength in the stock over the last nine months has appropriately priced in the company's growth rate, said Miller, who maintains a $118 price target on Disney shares. 2. Groupon (GRPN) downgraded to Underweight on lackluster ad spend at Morgan Stanley with analyst Brian Nowak saying its recent local advertiser survey indicate lackluster forward advertiser spending and believes Groupon will need to spend more in order to grow North America Local Billings, which the Street seems to be underestimating. 3. Grainger (GWW) downgraded to Market Perform from Outperform at William Blair with analyst Ryan Merkel citing a lack of confidence in the company's repricing strategy. 4. Bank of America (BAC) downgraded to Hold from Buy at Berenberg with analyst James Chappell saying it is time to take profits. Interest rates unlikely to rise as much as has been priced into bank equity valuations, Chappell tells investors in a research note. Further, regulation and tax reform are likely to take longer than expected and not be as beneficial for the banks as many might have hoped, the analyst adds. He upped his price target for Bank of America shares to $22 from $15. 5. DuPont Fabros (DFT) downgraded to Hold from Buy at Stifel with analyst Matthew Heinz saying shares are fully valued and demand patterns have shifted. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/24/17
BREN
04/24/17
DOWNGRADE
Target $22
BREN
Hold
Bank of America downgraded to Hold from Buy at Berenberg
Berenberg analyst James Chappell downgraded Bank of America to Hold saying it is time to take profits. Interest rates unlikely to rise as much as has been priced into bank equity valuations, Chappell tells investors in a research note. Further, regulation and tax reform are likely to take longer than expected and not be as beneficial for the banks as many might have hoped, the analyst adds. He upped his price target for Bank of America shares to $22 from $15.
04/19/17
RBCM
04/19/17
NO CHANGE
RBCM
Bank of America reported 'knockout' results, says RBC Capital
RBC Capital analyst Gerard Cassidy says that Bank of America reported "knockout" Q1 results that were better than the other three "Big Four" banks. The analyst says that the company has momentum heading into the rest of the year. He keeps a $26 price target and an Outperform rating on the shares.
06/09/17
RBCM
06/09/17
NO CHANGE
RBCM
House financial reform bill unlikely to advance in Senate, says RBC Capital
RBC Capital analyst Gerard Cassidy says that the financial regulation reform bill passed yesterday by the House would help the banking sector but probably won;t be passed by the Senate. Large publicly traded banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
ETFC E-Trade
$37.68

-0.01 (-0.03%)

03/02/17
SDLR
03/02/17
DOWNGRADE
SDLR
Hold
E-Trade downgraded to Hold from Buy at Sandler O'Neill
03/13/17
UBSW
03/13/17
INITIATION
Target $43
UBSW
Buy
E-Trade initiated with a Buy at UBS
UBS analyst Brennan Hawken started E-Trade Financial with a Buy rating and $43 price target. New management's plan to improve operating metrics or seek a buyer for the franchise should help limit the stock downside, Hawken tells investors in a research note.
03/13/17
03/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BofA Merrill Lynch analyst Kevin Fischbeck assumed coverage of Cigna (CI) with a Buy rating and $175 price target. The company's core business continues to improve, which will drive above average earnings growth in 2017, the analyst contends. 2. Canaccord Genuity analyst Richard Close started Health Insurance Innovations (HIIQ) with a Buy rating and $28 price target. Deregulation under the Trump administration provides a favorable growth outlook for the company's insurance sales, the analyst said. 3. Jefferies analyst Philippe Houchois started Ferrari (RACE) with a Buy rating and $74 price target. 4. Baird analyst Mircea Dobre started John Bean Technologies (JBT) with an Outperform rating and $101 price target, while Wells Fargo analyst Allison Poliniak-Cusic started John Bean Technologies with an Outperform rating and $100-$102 price target range. 5. UBS analyst Brennan Hawken started E-Trade Financial (ETFC) with a Buy rating and $43 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/19/17
DBAB
05/19/17
NO CHANGE
DBAB
E-Broker selloff a buying opportunity, says Deutsche Bank
Deutsche Bank analyst Brian Bedell views the midweek selloff in shares of Charles Schwab (SCHW) and E-Trade (ETFC) as a buying opportunity. The analyst does not see the political uncertainty significantly derailing the Fed tightening cycle. The stocks look attractive even under scenario of only three more Fed hikes through 2018, Bedell tells investors in a research note.
RAD Rite Aid

06/30/17
EVER
06/30/17
INITIATION
EVER
Underperform
Rite Aid reinstated with an Underperform at Evercore ISI
Evercore ISI analyst Ross Muken reinstated Rite Aid with an Underperform rating, versus In-Line previously, to reflect threats from online competition, structural challenges at the back-end of pharmacy given network positioning, and limited strategic options. The analyst sees downside near-term to $2.00-$2.50 per share.
06/30/17
COWN
06/30/17
NO CHANGE
Target $5
COWN
Outperform
Rite Aid better positioned following new agreement, says Cowen
Cowen analyst Charles Ryhee said he is positive on the new Rite Aid (RAD) agreement with Walgreens (WBA) as it better positions the company than had it remained stand-alone with no deal at all. Benefits include deleveraging, lower generic procurement costs, increased financial flexibility and "great" leverage toward PBM, which is growing faster than retail. Ryhee reiterated his Outperform rating and $4.70 price target on Rite Aid shares.
06/29/17
JEFF
06/29/17
NO CHANGE
Target $95
JEFF
Buy
Jefferies sees Walgreens topping new synergy target
Jefferies analyst Brian Tanquilut fully expects Walgreens Boots Alliance (WBA) to exceed its new synergy target from the purchase of Rite Aid (RAD) stores. He also expects the FTC to approve the new agreement as he thinks Walgreens wouldn't have entered into it if the agency wasn't fully aware and on-board with the revised transaction. The analyst views the recent pullback in Walgreens shares as overdone and keeps a Buy rating on the name with a $95 price target.
06/29/17
DBAB
06/29/17
NO CHANGE
Target $8
DBAB
Hold
Fred's price target lowered to $8 from $16 at Deutsche Bank
Deutsche Bank analyst Paul Trussell halved his price target for Fred's (FRED) to $8 after the company's asset purchase in connection with the failed Walgreens Boots Alliance (WBA), Rite Aid (RAD) merger was terminated. Fred's is now left to execute its pharmacy transformation organically, Trussell tells investors in a research note. He believes the company faces increasing competition in the dollar store space and keeps a Hold rating on the name.
CARA Cara Therapeutics
$25.51

-1.44 (-5.34%)

06/30/17
PIPR
06/30/17
NO CHANGE
Target $27
PIPR
Overweight
Cara Therapeutics selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Charles Duncan believes last night's Phase II trial results from Cara Therapeutics with oral CR845 in osteoarthritis hip and knee pain are "encouraging" at the highest 5mg dose. These results suggest oral CR845 has analgesic efficacy, with a differentiated safety/tolerability profile for a chronic agent, Duncan tells investors in a research note. He recommends using any stock weakness as a buying opportunity and keeps an Overweight rating on Cara with a $27 price target.
06/30/17
HCWC
06/30/17
NO CHANGE
Target $30
HCWC
Buy
Cara study results 'could have been far worse,' says H.C. Wainwright
H.C. Wainwright analyst Corey Davis says that even though Cara Therapeutics missed the primary endpoint in its Phase 2 study with oral CR845 in osteoarthritis pain, the company "unequivocally showed" a positive signal in the pre-specified subset of patients with hip osteoarthritis, but not knee. Most importantly, CR845 showed an "incredibly benign side effect profile," Davis tells investors in a research note. The analyst calls CR845 the first ever successful proof of concept study for an oral kappa opioid with virtually no side effects. The study "could have been far worse," and while not an obvious win that allows progression to Phase 3, the next step will be to conduct another Phase 2 with changes that can optimize the chances of CR845 showing clear efficacy. Davis keeps a Buy rating on Cara shares with a $30 price target. The stock in premarket trading is down 29%, or $7.52, to $17.99.
06/30/17
JANY
06/30/17
DOWNGRADE
Target $21
JANY
Neutral
Cara Therapeutics downgraded to Neutral from Buy at Janney Capital
Janney Capital analyst Ken Trbovich said the results of Cara Therapeutics' first placebo-controlled study of oral CR845 do not mean the end to development of the agent for chronic pain, but they also do not allow Cara to advance to a pivotal study next year, as he believes investors were expecting. Given that the pivotal study for this program has been pushed out to 2019/2020 from 2018 and that these results, combined with the decision a week ago to increase enrollment in the ongoing adaptive Phase 3 study of I.V. CR845 in postsurgical pain, gives him less confidence in a positive outcome for the Phase 3 than he'd previously had, Trbovich downgraded Cara to Neutral from Buy and lowered his fair value estimate to $21 from $22.
06/28/17
JANY
06/28/17
NO CHANGE
Target $22
JANY
Buy
Janney says Cara rise to as high as $36/share justified if OA data positive
Cara Therapeutics has indicated it anticipates reporting results from its Phase 2 study of oral CR845 for osteoarthritis by the end of Q2 and with the quarter nearing an end Janney Capital analyst Ken Trbovich said he expects "significant volatility" in the stock as the data is awaited. Positive results can "easily justify a move to the range of $31-$36/share," while the stock could trade down to $10-$15 per share on negative results, Trbovich tells investors. He keeps a Buy rating and $22 price target on Cara shares.

TODAY'S FREE FLY STORIES

TGT

Target

$60.08

0.05 (0.08%)

10:42
10/19/17
10/19
10:42
10/19/17
10:42
Hot Stocks
Target says small-format store in Herald Square to open October 20 »

Target tweeted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

UAL

United Continental

$63.93

-4.06 (-5.97%)

10:40
10/19/17
10/19
10:40
10/19/17
10:40
Hot Stocks
United Continental says Q3 involuntary denied boardings down 92% y/y »

Says employees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

VRX

Valeant

$12.10

-0.29 (-2.34%)

10:40
10/19/17
10/19
10:40
10/19/17
10:40
Options
Higher options volume in Valeant as one player banks a big profit »

Higher options volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

BP

BP

$38.81

0.09 (0.23%)

10:36
10/19/17
10/19
10:36
10/19/17
10:36
Hot Stocks
BP chairman Carl-Henric Svanberg announces intention to retire »

BP announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$121.99

-0.09 (-0.07%)

, AGCO

Agco

$70.84

-0.91 (-1.27%)

10:33
10/19/17
10/19
10:33
10/19/17
10:33
Hot Stocks
Monsanto's Climate Corp announces data connectivity agreement with Agco »

The Climate Corporation,…

MON

Monsanto

$121.99

-0.09 (-0.07%)

AGCO

Agco

$70.84

-0.91 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

FCEL

FuelCell

$2.13

0.09 (4.41%)

10:31
10/19/17
10/19
10:31
10/19/17
10:31
Hot Stocks
FuelCell to supply power to Navy base in Connecticut »

FuelCell Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

10:30
10/19/17
10/19
10:30
10/19/17
10:30
General news
EIA natural gas storage change for week ending October 13 »

Gas inventories 51 Bcf…

MU

Micron

$41.65

1.26 (3.12%)

10:30
10/19/17
10/19
10:30
10/19/17
10:30
Options
Active trading in Micron calls as shares slump Thursday »

Active trading in Micron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

NKE

Nike

$52.21

-0.0915 (-0.17%)

, ADDYY

adidas

$112.54

-0.08 (-0.07%)

10:29
10/19/17
10/19
10:29
10/19/17
10:29
Hot Stocks
Goldman Sachs cuts Nike rating ahead of investor day on excess inventory »

This morning, Goldman…

NKE

Nike

$52.21

-0.0915 (-0.17%)

ADDYY

adidas

$112.54

-0.08 (-0.07%)

GRPN

Groupon

$5.00

0.05 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 01

    Nov

  • 16

    Nov

ULTA

Ulta Beauty

$200.90

2.59 (1.31%)

10:29
10/19/17
10/19
10:29
10/19/17
10:29
Rumors
Rumor moving shares of Ulta Beauty »

Rumor: Ulta Beauty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
10/19/17
10/19
10:25
10/19/17
10:25
General news
Today's U.S. reports »

Today's U.S. reports…

UAL

United Continental

$64.26

-3.73 (-5.49%)

10:23
10/19/17
10/19
10:23
10/19/17
10:23
Technical Analysis
Technical View: United Continental falls after results and outlook »

The company reported Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

MEIP

MEI Pharma

$2.48

0.15 (6.44%)

10:23
10/19/17
10/19
10:23
10/19/17
10:23
Hot Stocks
MEI Pharma's pracinostat granted EU orphan designation »

Pracinostat was granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$50.08

1.431 (2.94%)

10:20
10/19/17
10/19
10:20
10/19/17
10:20
Options
Notable ratio spread in Verizon as shares rally on earnings »

Notable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

10:20
10/19/17
10/19
10:20
10/19/17
10:20
General news
Treasury Action: yields resumed their slide »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

10:17
10/19/17
10/19
10:17
10/19/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
10/19/17
10/19
10:16
10/19/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.76

0.25 (0.39%)

, TEVA

Teva

$14.61

-0.01 (-0.07%)

10:15
10/19/17
10/19
10:15
10/19/17
10:15
Periodicals
Merck wins appeal to revive NuvaRing patent case against Teva, Bloomberg says »

An appeals court said a…

MRK

Merck

$63.76

0.25 (0.39%)

TEVA

Teva

$14.61

-0.01 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 27

    Oct

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

  • 30

    Nov

  • 02

    Feb

ADP

ADP

$113.93

0.21 (0.18%)

10:15
10/19/17
10/19
10:15
10/19/17
10:15
Hot Stocks
Pershing Square releases additional questions for ADP »

Pershing Square Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

10:15
10/19/17
10/19
10:15
10/19/17
10:15
General news
U.S. leading economic index fell 0.2% to 128.6 in September »

U.S. leading economic…

10:15
10/19/17
10/19
10:15
10/19/17
10:15
General news
Breaking General news story  »

Week of 10/13 EIA Natural…

GS

Goldman Sachs

$240.07

-1.96 (-0.81%)

10:13
10/19/17
10/19
10:13
10/19/17
10:13
Hot Stocks
Blankfein: 'Just left Frankfurt,' 'I'll be spending a lot more time there' »

Goldman Sachs Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

EVHC

Envision Healthcare

$40.70

0.05 (0.12%)

10:11
10/19/17
10/19
10:11
10/19/17
10:11
Periodicals
Starboard's Smith to pitch Envision Healthcare as long idea, Bloomberg says »

Starboard Value's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NNI

Nelnet

$51.05

-0.27 (-0.53%)

10:10
10/19/17
10/19
10:10
10/19/17
10:10
Upgrade
Nelnet rating change  »

Follow-up: Nelnet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.30

0.4 (3.36%)

10:10
10/19/17
10/19
10:10
10/19/17
10:10
Options
Short-term call buyer in Ceaser's opens a notable new position »

Short-term call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.